Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 18, 2021 8:30 AM EST
Get Alerts PAND Hot Sheet
Price: $60.05 --0%

Overall Analyst Rating:
    BUY (Down Down)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.

A live webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at A replay of the webcast will be available shortly following the presentation.

About Pandion TherapeuticsPandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit and engage with us on Twitter @PandionTX or on LinkedIn.

For further information, please contact:

Media:Kathryn MorrisThe Yates

Investors:Michelle AveryPandion 

Primary Logo

Source: Pandion Therapeutics, Inc.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Globe Newswire, Press Releases

Related Entities